Coldwell Susan E, Wilhelm Frank H, Milgrom Peter, Prall Christopher W, Getz Tracy, Spadafora Agnes, Chiu I-Yu, Leroux Brian G, Ramsay Douglas S
Department of Dental Public Health Sciences, University of Washington, Seattle, WA 98195, USA.
J Anxiety Disord. 2007;21(7):871-87. doi: 10.1016/j.janxdis.2007.01.001. Epub 2007 Jan 23.
To determine whether a benzodiazepine facilitates systematic desensitization, 144 subjects with dental injection phobia received systematic desensitization in combination with placebo or one of two doses of alprazolam (0.5mg or 0.75mg). Systematic desensitization therapy included computer-controlled presentation of digitized video segments followed by in vivo exposure segments, culminating in an actual dental injection. Subjects advanced to the next hierarchy segment when low anxiety was reported during a segment. Alprazolam and placebo groups progressed at the same rate. The 0.75mg group had elevated heart rates while watching video segments compared with placebo. In a subsequent behavioral avoidance test (during which subjects were randomized to a new drug condition), there was no indication that state-dependent learning had occurred. Dental fear was reduced similarly in all groups for 1 year after study completion. No advantage was found to combining alprazolam with systematic desensitization for dental injection phobia.
为了确定苯二氮䓬类药物是否有助于系统脱敏疗法,144名患有牙科注射恐惧症的受试者接受了系统脱敏疗法,并结合安慰剂或两种剂量(0.5毫克或0.75毫克)的阿普唑仑之一。系统脱敏疗法包括电脑控制呈现数字化视频片段,随后进行现场暴露片段,最终进行实际的牙科注射。当受试者在某一片段报告低焦虑时,进入下一个等级片段。阿普唑仑组和安慰剂组进展速度相同。与安慰剂相比,0.75毫克组在观看视频片段时心率升高。在随后的行为回避测试中(在此测试中,受试者被随机分配到一种新的药物状态),没有迹象表明发生了状态依存性学习。研究完成后1年内,所有组的牙科恐惧都有类似程度的减轻。未发现阿普唑仑与系统脱敏疗法联合用于治疗牙科注射恐惧症有任何优势。